---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-237196"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:40:33.836740+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Climb Bio outlines budoprutug development strategy; Phase 1b pMN data shows 60% remission

## Summary
- Approximately $218M cash at Sept 30, 2024; expected to fund operations through 2027.
- Phase 1b pMN: 3/5 patients achieved complete remission; rapid B-cell depletion and anti-PLA2R reductions.
- Plans to initiate Phase 1b SLE trial and Phase 2 ITP trial in first half 2025, subject to regulatory clearance.
- Subcutaneous formulation advancing; non-clinical data expected first half 2025.
- Full pMN Phase 1b data to be presented at ASN Kidney Week on Oct 24, 2024.

## SEC filing metadata
- accession: 0001193125-24-237196
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312524237196/0001193125-24-237196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312524237196/d889682d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-237196
- JSON: https://secwatch.observer/filing/0001193125-24-237196.json
- Plain text: https://secwatch.observer/filing/0001193125-24-237196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.